Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0220723 (
PCA
)
4,687
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A newly synthesized compound, [[3-(1H-tetrazol-5-yl)-phenyl] amino]oxoacetic acid n-butyl ester (
MTB
) has been demonstrated to be an orally active antiallergic agent. This compound inhibited the 48-hr passive cutaneous anaphylaxis (48-hr
PCA
) induced by IgE in rats. In guinea pigs,
MTB
also inhibited the 8-day passive cutaneous anaphylaxis (8-day
PCA
) and the 8-day passive systemic anaphylaxis induced by IgE. The compound partially inhibited the IgG-mediated 3-hr
PCA
in rats and guinea pigs, but failed to have any effect on the rabbit IgG-mediated 3-hr
PCA
in these animals. In the rat,
MTB
was not an antagonist of histamine or serotonin. The antiallergic effect of
MTB
was not mediated via any adrenergic mechanisms.
MTB
significantly inhibited histamine release from rat peritoneal cells induced by rat IgE in vitro.
...
PMID:Antiallergic properties of an orally effective agent, [[3-(1H-tetrazol-5-yl)-phenyl] amino] oxoacetic acid n-butyl ester. 618 23